Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

NCT00197015
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix®, M-M-R®II, VARIVAX®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
42
States / cities
Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

NCT00125099
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 21, 2026, 3:57 PM EDT
Terminated Phase 2 Interventional

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

NCT00485563
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Sep 21, 2026, 3:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511
View directory record Official record
Conditions
Herpes Simplex
Interventions
Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Not applicable Interventional

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

NCT00001078
View directory record Official record
Conditions
HIV Infections
Interventions
Hepatitis A Vaccine (Inactivated)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 21, 2026, 3:57 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

NCT07500506
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
7 Years and older
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
19
States / cities
Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

NCT02267733
View directory record Official record
Conditions
Influenza, Gammopathy
Interventions
Fluzone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

NCT02304185
View directory record Official record
Conditions
Healthy
Interventions
gp140, 50 mcg, gp140, 50 mcg + Adjuvant, gp140, 250 mcg, gp140, 250 mcg + Adjuvant, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208
View directory record Official record
Conditions
RSV
Interventions
RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

NCT01502735
View directory record Official record
Conditions
Dengue Fever
Interventions
DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00952276
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
15
States / cities
Anaheim, California • Fountain Valley, California • South Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional

Phase I Study of Safety and Immunogenicity of ADU-623

NCT01967758
View directory record Official record
Conditions
Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
Interventions
Cohort 1, Cohort 2, Cohort 3, Antibiotics
Biological · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Adult - Chiron Study of Bird Flu Vaccine

NCT00280033
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

NCT01215149
View directory record Official record
Conditions
HIV Infections
Interventions
Ad35-ENV vaccine, Ad26.ENVA.01 vaccine, Placebo Control
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

NCT01403155
View directory record Official record
Conditions
Healthy
Interventions
INO-3401 + EP
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Overland Park, Kansas • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of DAR-901

NCT02063555
View directory record Official record
Conditions
Tuberculosis
Interventions
DAR-901, BCG, Sterile saline
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)

NCT05268185
View directory record Official record
Conditions
COVID-19, Vaccine Reaction, COVID-19 Pandemic
Interventions
Moderna Booster Vaccine, Pfizer Booster Vaccine
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

NCT01518478
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluzone® Intradermal (Sanofi Pasteur Inc.)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer

NCT01440816
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Universal Anti-Viral Vaccine for Healthy Elderly Adults

NCT04441047
View directory record Official record
Conditions
Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia, Influenza, Human, ARDS, Human
Interventions
AlloStim
Drug
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Delray Beach, Florida • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

NCT03360708
View directory record Official record
Conditions
Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00334776
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 21, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin

NCT00812071
View directory record Official record
Conditions
Healthy
Interventions
RiVax
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 31 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chesapeake, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Sep 21, 2026, 3:57 PM EDT